Vertex focused on programs in CF, hepatitis C and autoimmune diseases in 2013 Vertex’s key strategies and business priorities include: Focusing investment on key development programs for: Cystic Fibrosis, CF: Vertex’s CF strategy is to provide benefit to as many CF patients as possible. Hepatitis C: Vertex’s strategy in hepatitis C is to develop new all-oral treatment regimens of 12 weeks or less in duration with a goal of providing a high viral cure rate and improved tolerability. In 2013, Autoimmune Diseases: Vertex’s strategy in autoimmune diseases is to maximize the value of VX-509 across multiple autoimmune diseases globally. The company will evaluate collaborative opportunities that provide funding and capabilities to broaden and accelerate global development of VX-509. Autoimmune Diseases: Maximizing revenues and cash flow from the appropriate use of INCIVEK®(telaprevir) and KALYDECO in the U.S. and Canada and from the growth of KALYDECO in Europe and other countries 4. Maintaining financial strength to support future growth and shareholder returns.
News For VRTX From The Last 14 Days
Check below for free stories on VRTX the last two weeks.